(Q66407875)

English

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

A Phase 1 Study to Assess Safety and Tolerability of Tremelimumab and Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant (HDT/ASCT) (English)

0 references

medical condition

multiple myeloma

0 references

country

United States of America

0 references

contributor to the creative work or subject

Multiple Myeloma Research Foundation

0 references

start time

13 December 2016

0 references

end time

16 February 2018

0 references

number of participants

6

0 references

research intervention

melphalan

0 references

clinical trial phase

phase I clinical trial

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02716805

0 references

(Q66407875)

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)